Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated November 19, 2007, reports on regulatory actions concerning the drug Prexige (lumiracoxib). The filing details the suspension of marketing and sales in the United Kingdom, Germany, and Austria pending a European Union regulatory review under the "Article 107 procedure."
Key Financial Metrics
The filing provides limited financial data specific to the reporting period:
- Prexige Net Sales (Europe): USD 8 million for the first nine months of 2007.
- 2006 Full Year Group Net Sales: USD 37.0 billion.
- 2006 Full Year Group Net Income: USD 7.2 billion.
- 2006 R&D Investment: Approximately USD 5.4 billion.
The filing text does not provide clear values for current period revenue, profit, cash flow, margins, debt, or liquidity beyond the historical 2006 figures and the specific Prexige sales data.
Material Changes and Regulatory Actions
Significant material changes involve the regulatory status of Prexige:
- Suspensions: Health regulators in the UK and Germany suspended marketing and sales. Austria requested a suspension pending a final decision by the Committee for Medicinal Products for Human Use (CHMP).
- EU Review: The CHMP initiated an Article 107 procedure on November 16, 2007, to review the drug's benefit/risk profile. An opinion is expected in December 2007.
- US Status: The US Food and Drug Administration (FDA) decided in September 2007 not to approve Prexige.
- Previous Actions: Prexige was withdrawn in Australia in August 2007 due to liver side effects at doses higher than 100 mg. An Urgent Safety Restriction was initiated in Europe in August 2007 for the 100 mg dose.
Outlook, Risks, and Management Commentary
Management Commentary: Novartis maintains that Prexige is a valuable treatment option with a positive benefit/risk ratio for appropriate patients. The company notes that liver enzyme changes are known side effects of all COX-2 inhibitors and NSAIDs, stating that available data suggest the 100 mg dose is not associated with increased hepatic risk compared to other NSAIDs.
Risks and Contingencies:
- Regulatory Risk: Other EU countries may independently suspend marketing authorization ahead of the CHMP decision.
- Safety Data: Nine severe hepatic events have been reported worldwide for the 100 mg dose (rate of 5.19 per 100,000 patient-years), which is within the expected rate for NSAIDs. No deaths have been reported worldwide with the 100 mg dose.
- Forward-Looking Statements: The filing includes a disclaimer that future regulatory filings may not satisfy requirements, approvals are not guaranteed, and sales levels are uncertain due to regulatory delays, public debate on COX-2 inhibitors, and competition.
Key Facts for Investor Verification
- Verify the final outcome of the CHMP Article 107 review expected in December 2007.
- Monitor whether other EU member states follow the UK, Germany, and Austria in suspending Prexige sales.
- Assess the potential financial impact of the suspension on the company's overall portfolio, noting Prexige contributed USD 8 million in European sales for the first nine months of 2007.
- Review ongoing discussions with the FDA regarding the September 2007 non-approval decision.
- Confirm if any new safety data emerges regarding hepatic events for the 100 mg dose during the review period.